Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of…